SPHS - Sophiris Bio, Inc.
| Previous Close | 0.9900 |
| Open | 0.9881 |
| Bid | 0.7800 x 900 |
| Ask | 1.0400 x 1300 |
| Day's Range | 0.9701 - 1.0100 |
| 52 Week Range | 0.7100 - 3.4900 |
| Volume | 55,287 |
| Avg. Volume | 146,696 |
| Market Cap | 28.901M |
| Beta (3Y Monthly) | 3.15 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0620 |
| Earnings Date | Nov 9, 2018 - Nov 12, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.75 |
- PR Newswire
Sophiris Bio Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights
SAN DIEGO and VANCOUVER, British Columbia , Aug. 9, 2019 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin ...
- Zacks Small Cap Research
SPHS: Details of Phase 3 Prostate Cancer Trial Based on Positive EMA Feedback…
Sophiris Bio Inc. (SPHS) is developing treatments for localized clinically significant prostate cancer and lower urinary tract symptoms of benign prostatic hyperplasia (BPH). The company’s lead candidate, topsalysin (PRX302), is a genetically engineered recombinant protein that is activated through enzymatic cleavage by prostate specific antigen (PSA), which is produced in large quantities by the prostate gland. The compound showed a 27% response rate in a Phase 2b clinical trial in patients with localized clinically significant prostate cancer and Sophiris is currently preparing for a Phase 3 clinical trial.
- PR Newswire
Sophiris Bio Receives Positive Feedback from European Medicines Agency Regarding Phase 3 Localized Prostate Cancer Clinical Trial Design
SAN DIEGO and VANCOUVER, British Columbia, June 19, 2019 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, today announced that it has received formal scientific advice from the European Medicines Agency (EMA) regarding a proposed design of a Phase 3 clinical trial to evaluate the potential of topsalysin as a targeted focal therapy to treat patients with intermediate risk localized prostate cancer. "Based on the safety profile of topsalysin in 451 patients in our clinical development program along with the efficacy seen in our Phase 2 studies in localized prostate cancer, we approached the EMA with our proposed study design for a single Phase 3 trial to support registration in Europe, and we are pleased to have now obtained formal feedback from the Agency," said Randall Woods, president and CEO of Sophiris.
- Simply Wall St.
Some Sophiris Bio (FRA:BFF1) Shareholders Have Taken A Painful 79% Share Price Drop
Even the best investor on earth makes unsuccessful investments. But it's not unreasonable to try to avoid truly...
- Zacks Small Cap Research
SPHS: EMA Guidance on Phase 3 Clinical Trial for Topsalysin Expected in 2Q19…
Sophiris Bio Inc. (SPHS) is developing treatments for localized clinically significant prostate cancer and lower urinary tract symptoms of benign prostatic hyperplasia (BPH). The company’s lead candidate, topsalysin (PRX302), is a genetically engineered recombinant protein that is activated through enzymatic cleavage by prostate specific antigen (PSA), which is produced in large quantities by the prostate gland. The compound showed a 27% response rate in a Phase 2b clinical trial in patients with localized clinically significant prostate cancer and Sophiris is currently preparing for a Phase 3 clinical trial.
- PR Newswire
Sophiris Bio Reports First Quarter 2019 Financial Results
SAN DIEGO and VANCOUVER, British Columbia , May 9, 2019 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company," "We" or "Sophiris"), a biopharmaceutical company developing ...
- PR Newswire
Sophiris Bio to Present at Two Upcoming Investor Conferences
SAN DIEGO and VANCOUVER, British Columbia, April 2, 2019 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, today announced that Randall E. Woods, president and chief executive officer, will present at two upcoming healthcare-focused investor conferences. On Monday, April 8, 2019, Mr. Woods will present a corporate overview at the H.C. Wainwright Global Life Sciences Conference at 12:10 pm BST in London, England. On Wednesday, April 10, 2019, Mr. Woods will present a corporate overview at the 18th Annual Needham Healthcare Conference at 2:50 pm EDT in New York, NY.
- Zacks Small Cap Research
SPHS: Awaiting Regulatory Guidance for Topsalysin Phase 3 Study…
Sophiris Bio Inc. (SPHS) is developing treatments for localized clinically significant prostate cancer and lower urinary tract symptoms of benign prostatic hyperplasia (BPH). The company’s lead candidate, topsalysin (PRX302), is a genetically engineered recombinant protein that is activated through enzymatic cleavage by prostate specific antigen (PSA), which is produced in large quantities by the prostate gland. The compound showed a 27% response rate in a Phase 2b clinical trial in patients with localized clinically significant prostate cancer and Sophiris is currently preparing for a Phase 3 clinical trial.
- PR Newswire
Sophiris Bio Reports Fourth Quarter 2018 and Year-end Financial Results and Recent Corporate Highlights
SAN DIEGO and VANCOUVER, British Columbia, March 13, 2019 /PRNewswire/ -- Sophiris Bio Inc. (SPHS) (the "Company," "We" or "Sophiris"), a biopharmaceutical company developing topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, today reported financial results for the fourth quarter and full year 2018 and recent corporate highlights. "During the past year, Sophiris has made important progress in determining the ideal method for topsalysin administration as a focal treatment for localized prostate cancer," said Randall E. Woods, president and CEO of Sophiris. "The Phase 2b study provided a compelling look at this potential, showing that a single administration of topsalysin led to a clinical response in 27% of patients, including a complete ablation of tumor in 16% of patients.
- Zacks Small Cap Research
SPHS: Ready to Move Topsalysin into Phase 3 for Localized Clinically Significant Prostate Cancer…
A total of 38 patients received a single administration of topsalysin to treat a clinically significant tumor, which was defined for this study as either a Gleason score of 6 (pattern 3 + 3) and greater than or equal to 6 mm maximum cancer core length (MMCL), or a Gleason score of 7 (pattern 3 + 4) and less than or equal to 10 mm MCCL. Ten patients received a second administration of topsalysin due to having a partial response to the first treatment, however their lesions were still clinically significant.
- PR Newswire
Sophiris Bio Provides Updates on Phase 2b Localized Prostate Cancer Trial
SAN DIEGO and VANCOUVER, British Columbia, Dec. 17, 2018 /PRNewswire/ -- Sophiris Bio Inc. (SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, today provides an update from its Phase 2b study of topsalysin for localized prostate cancer, including top-line safety and biopsy results from the patients who received a second administration of study drug, which appeared to be safe and generally well-tolerated. Additional benefit was not observed on targeted biopsy six months after re-treatment with a second administration of topsalysin. As previously stated, a total of 27% of patients (10/37) demonstrated a clinical response six months following a single administration of topsalysin.
- Simply Wall St.
Does Sophiris Bio Inc (FRA:BFF1) Have A Volatile Share Price?
If you own shares in Sophiris Bio Inc (FRA:BFF1) then it's worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure Read More...
- Zacks Small Cap Research
SPHS: Data from Second Administration of Topsalysin in Phase 2b Trial Anticipated Before End of 2018…
By David Bautz, PhD NASDAQ:SPHS READ THE FULL SPHS RESEARCH REPORT Business Update Interim Safety and Efficacy Data for Phase 2b Trial of Topsalysin in Localized Prostate Cancer Earlier in 2018, Sophiris ...
- GlobeNewswire
Report: Exploring Fundamental Drivers Behind HC2, Pangaea Logistics Solutions, Sophiris Bio, Acacia Research, JAKKS Pacific, and LeMaitre Vascular — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Nov. 16, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- PR Newswire
Sophiris Bio to Present at the Piper Jaffray Healthcare Conference
SAN DIEGO and VANCOUVER, British Columbia, Nov. 15, 2018 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, today announced that Randall E. Woods, president and chief executive officer, will present a corporate overview at the Piper Jaffray Healthcare Conference on Tuesday, November 27, 2018 at 2:00 p.m. ET in New York, NY. A replay of the presentation will be available on the Company's website for 90 days.
- PR Newswire
Sophiris Bio Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights
SAN DIEGO and VANCOUVER, British Columbia , Nov. 13, 2018 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin ...
- PR Newswire
Sophiris Bio to Present at the Cantor Global Healthcare Conference
SAN DIEGO and VANCOUVER, British Columbia, Sept. 25, 2018 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, today announced that Randall E. Woods, president and chief executive officer, will present a corporate overview at the Cantor Global Healthcare Conference on Tuesday, October 2, 2018 at 4:35 p.m. EDT in New York, NY. A replay of the presentation will be available on the Company's website for 90 days.
- PR Newswire
Sophiris Bio Extends the Interest Only Period under its Loan and Security Agreement
SAN DIEGO and VANCOUVER, British Columbia, Sept. 14, 2018 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, today announced that it has met the requirements within its existing loan and security agreement with Silicon Valley Bank ("SVB") to extend the interest only periods between September 30, 2018 and March 31, 2019. The Company will begin making interest and principal payments starting on April 1, 2019 and ending on the final payment date of September 1, 2021. The extension of this interest only period allows the Company to shift principal payments of $1.2 million, which would have been due during the periods between September 30, 2018 and March 31, 2019, to periods after April 1, 2019.
- Zacks Small Cap Research
SPHS: Patient Death in Phase 2b Trial Unlikely Related to Topsalysin Treatment…
On August 29, 2018, Sophiris Bio, Inc. (SPHS) announced the result of an investigation into the previously announced patient death in the ongoing Phase 2b trial of topsalysin (PRX302) in localized clinically significant prostate cancer. After reviewing the autopsy report, hospital records, and hypersensitivity tests, it was determined that the patient’s death was unlikely the result of topsalysin or the procedure. The official cause of death listed on the autopsy report is Sudden Cardiac Deach (SCD) probably due to arrhythmia and the patient had a number of risk factors for SCD.
- ACCESSWIRE
Today’s Research Reports on Stocks to Watch: Opiant Pharmaceuticals and Sophiris Bio
NEW YORK, NY / ACCESSWIRE / August 30, 2018 / Shares of Opiant saw big gains after Wall Street learned that Emergent Biosciences Inc. announced the acquisition of Adapt Pharma® for $635 million. Adapt markets NARCAN® Nasal Spray for the treatment of opioid overdose, for which Opiant Pharmaceuticals, Inc. receives tiered royalties. Shares of Sophiris Bio also saw big gains after announcing updates on a phase 2b Localized Prostate Cancer Trial.
- PR Newswire
Sophiris Bio to Present at the H.C. Wainwright 20th Annual Global Investment Conference
SAN DIEGO and VANCOUVER, British Columbia , Aug. 29, 2018 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin ...
- PR Newswire
Sophiris Bio Updates on Phase 2b Localized Prostate Cancer Trial
SAN DIEGO and VANCOUVER, British Columbia, Aug. 29, 2018 /PRNewswire/ -- Sophiris Bio Inc. (SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, today announced the conclusion of the ongoing investigation into the previously reported death of a patient in the Company's Phase 2b trial for the treatment of localized prostate cancer is unlikely to be related to either topsalysin or the procedure. The regulatory authorities in the United States and the United Kingdom where the study is being conducted have been notified. Following a comprehensive review of the recently received autopsy report, together with hospital records and the negative serology results for acute hypersensitivity, the Investigator and Company believe that the cause of death is consistent with the autopsy finding of Sudden Cardiac Death (SCD) probably due to an arrhythmia.
